Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01182415 · OUTCOME

2-year Progression Free Survival (PFS)

High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma · Source last updated 2023-04-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
2 years

What was measured

The percentage of participants alive and without disease progression at 2 years. Disease progression was judged through clinical impression and MRI imaging.

Analysis population: The participant that was lost to follow-up was not available for analysis.

Groups in this outcome

High-dose Chemotherapy With Autologous Stem Cell Transplant

Autologous stem cell transplant: Autologous stem cell transplant following high-dose chemotherapy High-dose chemotherapy: High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
High-dose Chemotherapy With Autologous Stem Cell Transplant29

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
High-dose Chemotherapy With Autologous Stem Cell Transplant81Not reported5992Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        59
        upper Limit
        92
        value
        81
denoms
  1. counts
    1. group Id
      OG000
      value
      29
    units
    Participants
description
The percentage of participants alive and without disease progression at 2 years. Disease progression was judged through clinical impression and MRI imaging.
dispersion Type
95% Confidence Interval
groups
  1. description
    Autologous stem cell transplant: Autologous stem cell transplant following high-dose chemotherapy High-dose chemotherapy: High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide
    id
    OG000
    title
    High-dose Chemotherapy With Autologous Stem Cell Transplant
param Type
NUMBER
population Description
The participant that was lost to follow-up was not available for analysis.
reporting Status
POSTED
time Frame
2 years
title
2-year Progression Free Survival (PFS)
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice